Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.
- Published In:
- JBMR plus, 6(9), e10665 (2022)
- Database ID:
- RPEP-06268
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06268APA
Krege, John H; Gilsenan, Alicia W; Komacko, John L; Kellier-Steele, Nicole. (2022). Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.. JBMR plus, 6(9), e10665. https://doi.org/10.1002/jbm4.10665
MLA
Krege, John H, et al. "Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.." JBMR plus, 2022. https://doi.org/10.1002/jbm4.10665
RethinkPeptides
RethinkPeptides Research Database. "Teriparatide and Osteosarcoma Risk: History, Science, Elimin..." RPEP-06268. Retrieved from https://rethinkpeptides.com/research/krege-2022-teriparatide-and-osteosarcoma-risk
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.